Esseltine, D-L.

(Dixie Esseltine)

patient bortezomib myeloma response study trial dexamethasone therapy neuropathy blood treatment analysis phase richardson grade journal survival sample signi disease bene ﬁt impairment month british journal table incidence cycle signi ﬁcantly expression cancer result research baseline dose modi ﬁcation progression high-dose thalidomide event classi response rate ef ﬁcacy dexamethasone patients quality figure erasmus mc high-dose dexamethasone ﬁcation haematology group marrow grade ‡2 bortezomib arm genomic england journal millennium pharmaceuticals myeloma patients dose-modi ﬁcation guideline proteasome number british cohort subgroups factor platelet bortezomib patients te complications anderson combination blade gene expression score tumor ﬁcantly prognostic population summit lonial inhibition reduction publishing

7 Most Recent Publications

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline (Article) Richardson, P.G. Sonneveld, P. Bladé, J. Boccadoro, M. Cavenagh, J. Boral, A.L. Esseltine, D-L. Wen, P.Y. Amato, A.A. Anderson, K.C. San Miguel, J-F. Schuster, M.W. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. Reece, D.	2009-03-01
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma (Article) Lonial, S. Richardson, P.G. Anderson, K.C. Harousseau, J-L. San Miguel, J-F. Sonneveld, P. Schuster, M.W. Bladé, J. Cavenagh, J. Rajkumar, S.V. Jakubowiak, A.J. Esseltine, D-L.	2008-10-01
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (Article) Niesvizky, R. Richardson, P.G. Harousseau, J-L. Boral, A.L. Esseltine, D-L. Anderson, K.C. Bladé, J. Rajkumar, S.V. Coleman, M. Rosiñol, L. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T.	2008-10-01
Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study (Article) San Miguel, J-F. Richardson, P.G. Goldschmidt, H. Reece, D. Bladé, J. Boccadoro, M. Cavenagh, J. Neuwirth, R. Boral, A.L. Esseltine, D-L. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S.	2008-04-01
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial (Article) Richardson, P.G. Sonneveld, P. Reece, D. San Miguel, J-F. Bladé, J. Boccadoro, M. Cavenagh, J. Alsina, M. Rajkumar, S.V. Lacy, M. Jakubowiak, A.J. Dalton, W. Schuster, M.W. Boral, A.L. Esseltine, D-L. Schenkein, D. Anderson, K.C. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H.	2007-11-15
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients (Article) Zangari, M. Esseltine, D-L. Cavallo, F. Neuwirth, R. Elice, F. Burns, M.J. Yaccoby, S. Richardson, P.G. Sonneveld, P. Tricot, G.	2007-09-01
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib (Article) Mulligan, G. Mitsiades, C. Trepicchio, W.L. Broyl, A. Sonneveld, P. Shaughnessy, J. Bergsagel, P.L. Schenkein, D. Esseltine, D-L. Boral, A.L. Anderson, K.C. Bryant, B. Zhan, F. Chng, W.J. Roels, S. Koenig, E. Fergus, A. Huang, Y. Richardson, P.G.	2007-04-15

Message*:
Your Email Adress*:
	*: Required fields, please provide an email address so that the RePub team can contact you if needed.